jazz pharmaceuticals - JAZZ
JAZZ
Close Chg Chg %
125.10 1.57 1.25%
Closed Market
126.67
+1.57 (1.25%)
Volume: 903.13K
Last Updated:
Nov 22, 2024, 4:00 PM EDT
Company Overview: jazz pharmaceuticals - JAZZ
JAZZ Key Data
| Open $125.76 | Day Range 124.91 - 127.61 |
| 52 Week Range 99.06 - 134.17 | Market Cap $7.56B |
| Shares Outstanding 60.45M | Public Float 58.21M |
| Beta 0.57 | Rev. Per Employee N/A |
| P/E Ratio 18.02 | EPS $7.45 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 689.33K |
JAZZ Performance
| 1 Week | 4.13% | ||
| 1 Month | 15.63% | ||
| 3 Months | 11.24% | ||
| 1 Year | 4.38% | ||
| 5 Years | -13.41% |
JAZZ Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
21
Full Ratings ➔
About jazz pharmaceuticals - JAZZ
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
JAZZ At a Glance
Jazz Pharmaceuticals Plc
Waterloo Exchange
Dublin, Dublin 4
| Phone | 353-1-634-7800 | Revenue | 3.83B | |
| Industry | Pharmaceuticals: Major | Net Income | 414.83M | |
| Sector | Health Technology | 2023 Sales Growth | 4.778% | |
| Fiscal Year-end | 12 / 2024 | Employees | 2,800 | |
| View SEC Filings |
JAZZ Valuation
| P/E Current | 18.018 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 20.159 |
| Price to Sales Ratio | 2.312 |
| Price to Book Ratio | 2.049 |
| Price to Cash Flow Ratio | 8.117 |
| Enterprise Value to EBITDA | 10.042 |
| Enterprise Value to Sales | 3.40 |
| Total Debt to Enterprise Value | 0.445 |
JAZZ Efficiency
| Revenue/Employee | 1,369,358.571 |
| Income Per Employee | 148,154.286 |
| Receivables Turnover | 5.432 |
| Total Asset Turnover | 0.345 |
JAZZ Liquidity
| Current Ratio | 2.124 |
| Quick Ratio | 1.735 |
| Cash Ratio | 1.058 |
JAZZ Profitability
| Gross Margin | 72.775 |
| Operating Margin | 17.195 |
| Pretax Margin | 7.77 |
| Net Margin | 10.819 |
| Return on Assets | 3.732 |
| Return on Equity | 12.16 |
| Return on Total Capital | 4.351 |
| Return on Invested Capital | 4.67 |
JAZZ Capital Structure
| Total Debt to Total Equity | 155.115 |
| Total Debt to Total Capital | 60.802 |
| Total Debt to Total Assets | 50.877 |
| Long-Term Debt to Equity | 138.407 |
| Long-Term Debt to Total Capital | 54.253 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Jazz Pharmaceuticals - JAZZ
Collapse All in section
| All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 2.36B | 3.09B | 3.66B | 3.83B | |
Sales Growth
| +9.34% | +30.91% | +18.26% | +4.78% | |
Cost of Goods Sold (COGS) incl D&A
| 408.50M | 966.53M | 1.14B | 1.04B | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 278.25M | 552.48M | 629.47M | 638.70M | |
Depreciation
| 18.67M | 26.71M | 30.30M | 30.41M | |
Amortization of Intangibles
| 259.58M | 525.77M | 599.17M | 608.28M | |
COGS Growth
| -15.38% | +136.61% | +17.92% | -8.41% | |
Gross Income
| 1.96B | 2.13B | 2.52B | 2.79B | |
Gross Income Growth
| +16.44% | +8.83% | +18.42% | +10.74% | |
Gross Profit Margin
| +82.72% | +68.76% | +68.86% | +72.78% |
| 2020 | 2021 | 2022 | 2023 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 1.19B | 1.73B | 1.80B | 2.13B | |
Research & Development
| 335.38M | 505.75M | 590.45M | 849.66M | |
Other SG&A
| 854.23M | 1.22B | 1.21B | 1.28B | |
SGA Growth
| +14.75% | +45.29% | +4.11% | +18.42% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 367.55M | 248.59M | 806.30M | 67.16M | |
EBIT after Unusual Expense
| 397.92M | 150.69M | (86.13M) | 592.12M | |
Non Operating Income/Expense
| (26.52M) | 14.55M | 10.44M | 56.92M | |
Non-Operating Interest Income
| - | 1.80M | 11.50M | 65.10M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 96.31M | 278.08M | 297.10M | 351.12M | |
Interest Expense Growth
| +3.82% | +188.75% | +6.84% | +18.18% | |
Gross Interest Expense
| 96.31M | 278.08M | 297.10M | 351.12M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 275.10M | (112.84M) | (372.78M) | 297.93M | |
Pretax Income Growth
| -39.45% | -141.02% | -230.37% | +179.92% | |
Pretax Margin
| +11.64% | -3.65% | -10.19% | +7.77% | |
Income Tax
| 33.52M | 216.12M | (158.65M) | (119.91M) | |
Income Tax - Current - Domestic
| 110.90M | 88.85M | 37.82M | 20.80M | |
Income Tax - Current - Foreign
| 59.56M | 58.07M | 95.78M | 119.50M | |
Income Tax - Deferred - Domestic
| (29.49M) | (45.15M) | (8.88M) | (90.07M) | |
Income Tax - Deferred - Foreign
| (107.45M) | 114.35M | (283.37M) | (170.15M) | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 238.62M | (329.67M) | (224.06M) | 414.83M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| 238.62M | (329.67M) | (224.06M) | 414.83M | |
Net Income Growth
| -54.41% | -238.16% | +32.03% | +285.14% | |
Net Margin Growth
| +10.10% | -10.65% | -6.12% | +10.82% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 238.62M | (329.67M) | (224.06M) | 414.83M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 238.62M | (329.67M) | (224.06M) | 414.83M | |
EPS (Basic)
| 4.283 | -5.5226 | -3.5827 | 6.5544 | |
EPS (Basic) Growth
| -53.56% | -228.94% | +35.13% | +282.95% | |
Basic Shares Outstanding
| 55.71M | 59.69M | 62.54M | 63.29M | |
EPS (Diluted)
| 4.222 | -5.5226 | -3.5827 | 6.1015 | |
EPS (Diluted) Growth
| -53.57% | -230.81% | +35.13% | +270.30% | |
Diluted Shares Outstanding
| 56.52M | 59.69M | 62.54M | 72.07M | |
EBITDA
| 1.04B | 951.76M | 1.35B | 1.30B | |
EBITDA Growth
| +3.08% | -8.81% | +41.80% | -3.83% | |
EBITDA Margin
| +44.16% | +30.76% | +36.88% | +33.85% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 175.471 | |
| Number of Ratings | 21 | Current Quarters Estimate | 5.834 | |
| FY Report Date | 12 / 2024 | Current Year's Estimate | 20.274 | |
| Last Quarter’s Earnings | 6.61 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 18.29 | Next Fiscal Year Estimate | 21.648 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 16 | 7 | 16 | 17 |
| Mean Estimate | 5.83 | 4.46 | 20.27 | 21.65 |
| High Estimates | 6.19 | 5.17 | 20.56 | 24.24 |
| Low Estimate | 5.27 | 3.56 | 19.74 | 15.41 |
| Coefficient of Variance | 5.18 | 14.07 | 1.19 | 9.76 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 14 | 14 | 14 |
| OVERWEIGHT | 3 | 2 | 2 |
| HOLD | 4 | 4 | 4 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Jazz Pharmaceuticals - JAZZ
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Jazz Pharmaceuticals - JAZZ
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jun 12, 2024 | Patricia Carr SVP, Chief Accounting Officer | 6,596 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $108.82 per share | 717,776.72 |
| May 8, 2024 | Neena M. Patil EVP & Chief Legal Officer | 36,629 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $109.65 per share | 4,016,369.85 |
| Apr 10, 2024 | Renée D. Galá President & COO | 55,357 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $115.21 per share | 6,377,679.97 |
| Mar 11, 2024 | Patricia Carr SVP, Chief Accounting Officer | 8,364 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $117.51 per share | 982,853.64 |
| Mar 11, 2024 | Patricia Carr SVP, Chief Accounting Officer | 6,596 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $116.98 per share | 771,600.08 |
| Mar 8, 2024 | Bruce C. Cozadd Chairman & CEO; Director | 429,809 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $117.53 per share | 50,515,451.77 |
| Mar 8, 2024 | Robert Iannone EVP, Global Head of R&D | 62,226 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $117.53 per share | 7,313,421.78 |
| Mar 8, 2024 | Samantha Pearce SVP, Head of Europe & Internat | 16,922 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $117.53 per share | 1,988,842.66 |
| Mar 6, 2024 | Patrick Thomas Kennedy Director | 1,423 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2024 | Philip L. Johnson EVP & Chief Financial Officer | 15,932 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2024 | Philip L. Johnson EVP & Chief Financial Officer | 27,932 | Open market or private purchase of non-derivative security Non-derivative transaction at $119.65 per share | 3,342,063.80 |
| Mar 6, 2024 | Mary Elizabeth Henderson SVP, Technical Operations | 15,941 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Dec 7, 2023 | Jennifer E. Cook Director | 6,888 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $119.27 per share | 821,531.76 |
| Dec 7, 2023 | Mark Douglas Smith Director | 6,888 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $119.27 per share | 821,531.76 |